CryoPort, Inc. (NASDAQ:CYRX) Receives $10.88 Consensus Price Target from Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.88.

A number of analysts recently issued reports on the company. Roth Mkm reissued a "buy" rating and set a $15.00 target price on shares of CryoPort in a research note on Tuesday, April 1st. Morgan Stanley reduced their price target on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. UBS Group upped their price target on CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and set a $10.00 price target on shares of CryoPort in a research report on Wednesday, April 16th. Finally, BTIG Research reduced their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, July 7th.

CryoPort Trading Up 1.6%

Shares of CYRX stock traded up $0.12 on Wednesday, reaching $7.45. The company had a trading volume of 274,441 shares, compared to its average volume of 487,419. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. The stock has a market cap of $373.54 million, a PE ratio of -3.18 and a beta of 1.89. The company has a 50-day moving average of $6.80 and a 200-day moving average of $6.65. CryoPort has a 12 month low of $4.58 and a 12 month high of $9.78.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The business had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. On average, equities analysts forecast that CryoPort will post -0.99 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 16,344 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the sale, the chief executive officer owned 912,419 shares in the company, valued at approximately $6,441,678.14. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 13,321 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.01, for a total value of $93,380.21. Following the completion of the sale, the director owned 73,056 shares in the company, valued at approximately $512,122.56. This trade represents a 15.42% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 449,719 shares of company stock worth $3,042,327. 10.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in CryoPort by 0.4% during the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after buying an additional 1,512 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its position in CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares during the period. Sierra Summit Advisors LLC increased its position in CryoPort by 5.0% during the 1st quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company's stock worth $274,000 after buying an additional 2,150 shares during the period. Nebula Research & Development LLC increased its position in CryoPort by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after buying an additional 2,207 shares during the period. Finally, Avanza Fonder AB increased its position in CryoPort by 31.4% during the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company's stock worth $81,000 after buying an additional 2,601 shares during the period. Institutional investors own 92.90% of the company's stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.